中青年心肌梗死伴高胆固醇血症患者hsCRP及Hcy水平表达及抗血小板药物影响研究  

Study on the expression of hsCRP and Hcy in young and middle-aged patients with myocardial infarction and effects of antiplatelet drugs

作　　者：刘品刚[1] 陶亮亮 居峰[1] 万镇[1] 范修才[1] LIU Pingang;TAO Liangliang;JU Feng;WAN Zhen;FAN Xiucai(Department of Cardiovascular Medicine,Jianhu Hospital Affiliated to Nantong University,Yancheng,Jiangsu 224700,China)

机构地区：[1]南通大学附属建湖医院心血管内科

出　　处：《现代医药卫生》2020年第3期337-338,342,共3页Journal of Modern Medicine & Health

基　　金：江苏省盐城市科学技术局医学科技发展计划项目（YK2016107）

摘　　要：目的探讨中青年心肌梗死(MI)伴高胆固醇血症患者血清超敏C反应蛋白(hsCRP)及血浆同型半胱氨酸(Hcy)水平的表达及抗血小板药物的影响。方法选择2016年11月至2018年5月在该科住院的中青年MI伴高胆固醇血症患者106例,被随机均分为氯吡格雷组(B组)和替格瑞洛组(C组),在常规治疗基础上分别接受氯吡格雷、替格瑞洛治疗。另选择在该科住院的稳定性心绞痛伴高胆固醇血症患者53例作为对照组(A组),抗血小板药物仅服用阿司匹林。疗程均为2周。治疗前后比较各组患者的血清hsCRP及血浆Hcy水平。结果与治疗前比较,三组治疗2周后血清hsCRP及血浆Hcy水平均显著降低,差异均有统计学意义(P<0.05或0.01);与A、B组比较,C组血清hsCRP及血浆Hcy水平降低更显著,差异均有统计学意义(P<0.05或0.01)。结论应用替格瑞洛对中青年MI合并高胆固醇血症患者进行干预,在有效抗血小板治疗的同时可显著降低血清hsCRP及血浆Hcy水平,通过减轻炎性反应进一步改善患者的病情,为冠心病的治疗提供新的方法与思路。Objective To investigate the expression of serum hypersensitive c-reactive protein(hsCRP)and plasma homocysteine(Hcy)in young and middle-aged patients with myocardial infarction(MI)and hypercholesterolemia and the effect of antiplatelet drugs.Methods A total of 106 young and middle-aged MI patients with hypercholesterolemia admitted to the department from November 2016 to May 2018 were randomly divided into clopidogrel group(group B)and tigrel group(group C),respectively receiving clopidogrel and tigrel on the basis of conventional treatment.In addition,53 patients with stable angina combined with hypercholesterolemia hospitalized in the department were selected as the control group(group A).The course of treatment was 2 weeks.Serum hsCRP and plasma Hcy levels were compared before and after treatment.Results Compared with that before treatment,serum hsCRP and plasma Hcy levels in the three groups were significantly decreased after 2 weeks of treatment,with statistically significant differences(P<0.05 or 0.01).Compared with groups A and B,serum hsCRP and plasma Hcy levels in group C were significantly lower,with statistically significant differences(P<0.05 or 0.01).Conclusion The intervention of tigrello in young and middle-aged patients with MI and hypercholesterolemia can significantly reduce serum hsCRP and plasma Hcy levels while effective antiplatelet therapy,further improve the patients′condition by reducing inflammatory response,and provide new methods and ideas for the treatment of coronary heart disease.

关 键 词：急性心肌梗死 C反应蛋白质 同型半胱氨酸 替格瑞洛 

分 类 号：R542.22[医药卫生—心血管疾病]